Browse News
Filter News
Found 19 articles
-
Engitix Announces Appointment of Christopher Stevenson, Ph.D., as Chief Scientific Officer
9/5/2023
Engitix Ltd, a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary patient-centric human extracellular matrix platform, announces the appointment of Christopher Stevenson, Ph.D., as Chief Scientific Officer.
-
Citryll Announces Appointments of Eduardo Bravo as CEO and Tim Schenk as CBO
8/29/2023
Citryll announced the appointment of Eduardo Bravo as Chief Executive Officer.
-
Engitix Announces Appointment of Sonia Quaratino, M.D., Ph.D., as Independent Non-executive Director
5/9/2023
Engitix Ltd announces the appointment of Sonia Quaratino, M.D., PH.D., to its Board of Directors, as an independent non-executive director.
-
Ubix Therapeutics has announced a collaboration agreement with SK Biopharmaceuticals, and Engitix and Takeda are teaming up to develop a therapeutic for fibrostenotic IBD.
-
Engitix Announces Expanded Collaboration and Licensing Agreement with Takeda to Develop New Anti-Fibrotic Therapies in Inflammatory Bowel Disease
4/12/2022
Engitix Ltd, a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix platform, entered into an agreement with Takeda to expand an existing collaboration to now include the discovery and development of novel therapeutics for fibrostenotic inflammatory bowel disease, including Crohn’s disease and ulcerative colitis.
-
Money on the Move: January 19 – 25
1/26/2022
Temps are falling and so is investor cash. Here's which biotech companies are scooping up the dollars this week. -
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
The company plans to use the money to boost its drug discovery pipeline in fibrosis and cancer and expand its team, facilities and operations.
-
Engitix Announces $54m Series A Financing and a Strategic Collaboration with Dompé Farmaceutici Using Exscalate’s AI Supercomputing Power to Advance its Drug Discovery Pipeline in Fibrosis and Cancer
1/19/2022
Engitix Ltd, a biopharmaceutical company with a pioneering and proprietary human extracellular matrix drug target discovery platform announced the close of its $54m Series A financing as well as a strategic collaboration with Dompé farmaceutici S.P.A.
-
LabGenius Appoints Dr. Gino Van Heeke as Chief Scientific Officer
11/29/2021
LabGenius, the machine learning (ML)-driven protein engineering company, today announced the appointment of Gino Van Heeke Ph.D. as Chief Scientific Officer (CSO).
-
Engitix Therapeutics appoints Dr Mike Burbridge as VP Oncology and Immuno-oncology
5/4/2021
Engitix Ltd, a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours and with two significant partnerships based on its pioneering proprietary human extracellular matrix drug discovery platform, announced that it has appointed Dr Mike Burbridge, as Vice President, Oncology & Immuno-oncology.
-
Engitix Therapeutics to Relocate Headquarters to New Life Sciences Cluster, White City Place
12/15/2020
Engitix Ltd, a biotechnology company with a portfolio of programmes in fibrosis and solid tumours and two significant partnerships based on its proprietary human extracellular matrix platform, announced that it is relocating its headquarters and operations to WestWorks, White City Place.
-
Engitix Appoints Eduardo Bravo as Chairman of its Board of Directors
12/1/2020
Engitix Ltd, a biotechnology company with a portfolio of programmes in fibrosis and solid tumours and two significant partnerships based upon its proprietary human extracellular matrix platform, announced the appointment of Eduardo Bravo as Chairman of its Board of Directors.
-
Engitix Signs Collaboration and Licensing Agreement with Takeda to Develop Anti-Fibrotic Therapies in Advanced Liver Diseases
8/25/2020
Collaboration combines Engitix’s unique ECM platform with Takeda’s expertise in gastroenterology research and development and commercialisation
-
Engitix and Morphic Enter Research Collaboration to Identify ECM-Related Targets in Fibrostenotic Inflammatory Bowel Disease (IBD)
12/10/2019
Engitix Ltd and Morphic Therapeutic announce that they have entered into a research collaboration to identify ECM-related drug targets in fibrostenotic inflammatory bowel disease, an intestinal fibrosis complication that affects approximately 30 per cent of Crohn’s Disease patients.
-
Engitix Receives a Golden Ticket to LabCentral from Takeda to Advance Fibrosis and Solid Tumour Research
11/5/2019
Golden Ticket includes one year of lab bench space at Cambridge, MA-based shared laboratory and office space
-
Engitix Ltd Appoints Gino Van Heeke as Chief Scientific Officer
5/7/2019
Appointment of Gino Van Heeke, PhD, as Chief Scientific Officer (CSO), effective 7th May.
-
UCL Spin-out Engitix Closes £5m Financing to Progress Liver Disease and Pancreatic Cancer Drug Discovery Platform and Pipeline
11/27/2018
Engitix Ltd today announces it has closed a £5 million Series A financing, led by a private investor.
-
NeuroVive Appoints Recognized Scientific Advisors And Enters Research Agreements In NASH And Hepatocellular Carcinoma
2/22/2017